MedCity News
JUNE 16, 2023
Similarly, a 2019 study found rural residents had a five-year relative cancer survival that was 5.2% Trial access equity and inclusivity are important considerations for sponsors given the results of a 2021 analysis of U.S. lower than metropolitan or urban residents and a 10% increase in risk of death after adjustment for multiple factors.
Medgadget
MAY 2, 2023
While for other patients the possible adverse side effects from medication may prevent them from finding pharmacological therapies effective. Throughout 2016 and until mid-2019 we conducted a deep technology due diligence, as well as market research, and met and spoke with dozens of mental healthcare providers.
Pharmaceutical Technology
OCTOBER 10, 2022
In 2019, the agency authorized the use of Vyleesi, an injectable form of bremelanotide, for the same condition. What’s more, the World Health Organization did not include it in its 11th revision of the International Classification of Diseases (ICD-11) in 2019, she notes. There are no approved treatments in the EU.
Expert insights. Personalized for you.
114 
Let's personalize your content